Free Trial

Shire (SHP) Share Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
51,588 shs
Average Volume
3.14 million shs
Market Capitalization
£42.73 billion
P/E Ratio
Dividend Yield
Price Target
SHP stock logo

About Shire Stock (LON:SHP)

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

SHP Stock News Headlines

South Harz Potash Ltd SHP
URGENT: Prepare for Biden’s Digital Dollar NOW
Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.
URGENT: Prepare for Biden’s Digital Dollar NOW
Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.
See More Headlines
Receive SHP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Year Founded


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Market Cap
£42.73 billion
Not Optionable
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Flemming Ornskov M.P.H. (Age 60)
    MBA, M.D., MPH, CEO, MD & Exec. Director
  • Mr. Thomas J. W. Dittrich (Age 54)
    CFO & Director
  • Gisele Dion
    Chief Accounting Officer
  • Mr. Matthew Walker (Age 54)
    Head of Technical Operations
  • Dr. Andreas Busch Ph.D. (Age 55)
    Head of R&D and Chief Scientific Officer

Should I Buy Shire Stock? SHP Pros and Cons Explained


Here are some ways that investors could benefit from investing in Shire plc:

  • Shire plc has recently launched a groundbreaking new medication that is expected to revolutionize the treatment of a common disease.
  • The company's stock price has been steadily increasing over the past year, showing strong growth potential.
  • Shire plc has a strong track record of innovation and research in the pharmaceutical industry, making it a reliable investment option.
  • Recent acquisitions by Shire plc have expanded its market reach and diversified its product portfolio, reducing risk for investors.
  • Shire plc's financial reports indicate a healthy balance sheet and strong cash flow, providing stability for investors.


Investors should be bearish about investing in Shire plc for these reasons:

  • There is some uncertainty surrounding the regulatory approval of Shire plc's latest product, which could impact its market performance.
  • Competitive pressures in the pharmaceutical industry may affect Shire plc's market share and profitability in the future.
  • Fluctuations in currency exchange rates could impact Shire plc's international operations and financial results.
  • Shire plc faces potential litigation risks related to its products, which could lead to financial losses and damage to its reputation.
  • The overall economic environment and global health trends could influence the demand for Shire plc's products, affecting its revenue growth.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 22, 2024. Please send any questions or comments about these Shire pros and cons to

SHP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Shire own?
This page (LON:SHP) was last updated on 6/25/2024 by Staff

From Our Partners